Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies

Combination therapies consisting of immune checkpoint inhibitors plus anti-VEGF therapy show enhanced antitumor activity and are approved treatments for patients with renal cell carcinoma (RCC). The immunosuppressive roles of VEGF in the tumor microenvironment are well studied, but those of FGF/FGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Yusuke, Kamiyama, Hiroshi, Ichikawa, Kenji, Fukushima, Sayo, Ozawa, Yoichi, Yamaguchi, Shogo, Goda, Satoshi, Kimura, Takayuki, Kodama, Kotaro, Matsuki, Masahiro, Miyano, Saori Watanabe, Yokoi, Akira, Kato, Yu, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397636/
https://www.ncbi.nlm.nih.gov/pubmed/34753772
http://dx.doi.org/10.1158/0008-5472.CAN-20-2426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397636/
https://www.ncbi.nlm.nih.gov/pubmed/34753772
http://dx.doi.org/10.1158/0008-5472.CAN-20-2426

Ejemplares similares